← Leaderboards
Robert Rodick
Vxbiosciences, Inc.
$2,558,792
Attributed
$5,117,583
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2021–23$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
Funding mix
By agency
NIH$5,117,583 · 2
By mechanism
R01$4,817,583 · 1
R42$300,000 · 1
Top collaborators
- Leor S Weinberger3 shared
Others in their field
Other Emerging Leaders on “Virus”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$206,525,404
- Leonard Freedman · Leidos Biomedical Research, Inc.$79,828,969
- Ted Ross · University Of Georgia$71,962,304
- Beth Baseler · Leidos Biomedical Research, Inc.$67,833,289
- Tony Moody · Duke University$66,767,417
- Matthew Johnson · Duke University$61,899,930
Research focus
VirusDesignResistanceViral ResistanceDoseAntiviral TherapyMolecularProteinsRestViralVaccinesSafetyAntiviral AgentsEvolutionFormulationIn VivoAntiviral ResistanceEthicsEngineeringElementsEpidemiological ModelFirst-In-HumanAttenuated VaccinesComplement
Grant awards (3)
Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention$1,997,089
R01 · FY2023 · AI · contact PI
Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients$300,000
R42 · FY2023 · AI · contact PI
Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention$2,820,494
R01 · FY2021 · AI · contact PI